C4 Therapeutics Inc [CCCC] stock is trading at $6.45, up 14.97%. An important factor to consider is whether the stock is rising or falling in short-term value. The CCCC shares have gain 7.50% over the last week, with a monthly amount glided 19.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
C4 Therapeutics Inc [NASDAQ: CCCC] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $6 for it. Previously, Stifel upgraded its rating to Buy on December 13, 2023, and elevated its price target to $12. On February 24, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $10 on the stock. JP Morgan downgraded its rating to a Underweight and decreased its price target to $5 on February 24, 2023. JP Morgan downgraded its rating to a Neutral and reduced its price target to $15 on November 04, 2022. Morgan Stanley started tracking with a Underweight rating for this stock on October 11, 2022, and assigned it a price target of $6. In a note dated April 28, 2022, Credit Suisse initiated an Underperform rating and provided a target price of $10 on this stock.
C4 Therapeutics Inc [CCCC] stock has fluctuated between $1.06 and $11.88 over the past year. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $6.45 at the most recent close of the market. An investor can expect a potential return of 109.3% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
C4 Therapeutics Inc [NASDAQ:CCCC] reported sales of 33.67M for the trailing twelve months, which represents a growth of 38.75%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -3.54%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.42 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.73 points at the first support level, and at 5.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.84, and for the 2nd resistance point, it is at 7.24.
Ratios To Look Out For
For context, C4 Therapeutics Inc’s Current Ratio is 6.31. On the other hand, the Quick Ratio is 6.31, and the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 14.23, the price to book ratio is 1.88.
Transactions by insiders
Recent insider trading involved Salter Malcolm, Director, that happened on Oct 18 ’24 when 13000.0 shares were purchased. Director, Salter Malcolm completed a deal on Oct 11 ’24 to buy 8561.0 shares.
